CompletedPhase 2NCT00003783
Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia
Studying Precursor B-cell acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- William P. Bowman, MDCook Children's Medical Center - Fort Worth
- Intervention
- filgrastim(biological)
- Enrollment
- 36 target
- Eligibility
- 17 years · All sexes
- Timeline
- 1999 – 2007
Study locations (30)
- Arizona Cancer Center, Tucson, Arizona, United States
- Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
- Sutter Cancer Center, Sacramento, California, United States
- Kaiser Permanente-Southern California Permanente Medical Group, San Diego, California, United States
- Naval Medical Center - San Diego, San Diego, California, United States
- Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States
- Nemours Children's Clinic, Jacksonville, Florida, United States
- Sylvester Cancer Center, University of Miami, Miami, Florida, United States
- Baptist Hospital of Miami, Miami, Florida, United States
- Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
- Walt Disney Memorial Cancer Institute, Orlando, Florida, United States
- St. Mary's Hospital, West Palm Beach, Florida, United States
- Emory University Hospital - Atlanta, Atlanta, Georgia, United States
- Tripler Army Medical Center, Honolulu, Hawaii, United States
- Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003783 on ClinicalTrials.govOther trials for Precursor B-cell acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07441291CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCTPeking University People's Hospital
- RECRUITINGNANCT06689917JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ LeukemiaTongji Hospital
- RECRUITINGPHASE2NCT07244406Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALLHebei Senlang Biotechnology Inc., Ltd.
- RECRUITINGPHASE2NCT06554626Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLFirst Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE2NCT06111625Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALLSichuan University
- RECRUITINGPHASE1NCT04318678CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)St. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT03765177CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic MalignanciesOttawa Hospital Research Institute
- ENROLLING BY INVITATIONNCT03226704Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingNational Cancer Institute (NCI)
See all trials for Precursor B-cell acute lymphoblastic leukemia →